Journal article
In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk.
Abstract
CLINICAL IMPACT RATING: GIM/FP/GP: [Formula: see text].
Authors
Agarwal A; Padwal R
Journal
Annals of Internal Medicine, Vol. 178, No. 10,
Publisher
American College of Physicians
Publication Date
10 2025
DOI
10.7326/annals-25-03745-jc
ISSN
1056-8751